CDK4 and hepatocellular carcinoma: These data point to the fact that copanlisib used as a single agent affects the viability of HCC cells mainly by inducing cell cycle arrest by down-regulating CDK4/6 and cyclin D1, which are downstream targets of AKT, but only marginally effects apoptosis.